Trials / Active Not Recruiting
Active Not RecruitingNCT05602935
Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (estimated)
- Sponsor
- The Second Affiliated Hospital of Fujian Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, phase II study of camrelizumab combined with SOX regimen in subjects with resectable locally advanced gastric cancer. The patients will receive camrelizumab ,S-1 and oxaliplatin given every 3 weeks for 3 cycles as neoadjuvant therapy. After the surgery, adjuvant therapy which includes camrelizumab and SOX regimen will begin.
Conditions
- Stomach Neoplasms
- Digestive System Neoplasms
- Neoplasms
- Digestive System Diseases
- Stomach Diseases
- Neoplasms by Site
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | 200mg, intravenously, d1 |
| DRUG | SOX | SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle) |
| PROCEDURE | Surgery | Surgery |
Timeline
- Start date
- 2020-09-16
- Primary completion
- 2022-03-30
- Completion
- 2026-12-30
- First posted
- 2022-11-02
- Last updated
- 2023-09-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05602935. Inclusion in this directory is not an endorsement.